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Abstract  
The Authors discuss their experience in treating non-responder vitiligo patients with a UVA-1 laser. Laser Alba 
355® is an innovative device of target UVA - 1 phototherapy. The present report suggests that UVA1 laser could 
be an applicable therapeutic option in patients with vitiligo, also for the ones who did not respond to the more 
conventional phototherapies. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Vitiligo is an important cutaneous pigmentary 
disorder, characterised by the progressive loss of 
melanocytes and/or by their dysfunction, resulting in 
hypopigmented skin areas which progressively 
become amelanotic. Despite new researches and 
progress, the pathogenesis of vitiligo is still enigmatic. 
Nowadays most evidence support that vitiligo is a T - 
cell-mediated autoimmune disease, maybe triggered 
by oxidative stress, and associated with an underlying 
genetic predisposition [1][2][3][4]. 
Clinically, the condition is characterized by 
milk-white macules and patches, varying in size, form, 
and distribution. Because of the clinical appearance of 
the patients, vitiligo is often associated with 
psychological distress and reduction of patient’s life 
quality index [5]. 
Classically, vitiligo treatments are 
unsatisfactory and challenging. Despite the 
continuous introduction of innovative medical and 
surgical therapies, phototherapy is the mainstay of 
vitiligo repigmentation (Table 1) [6]. 
Table 1: Conventional phototherapies available for vitiligo 
treatment 
Phototherapies 
Broadband UVA 
PUVA therapy 
Topical PUVA 
PUVA sol therapy 
Bath PUVA 
Broadband UVB 
Narrow band UVB 
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The aim of this multicenter observational 
study was to evaluate the efficacy and safety of Laser 
Alba 355 in the treatment of 21 patients affected by 
vitiligo vulgaris, who had been unsuccessfully treated 
with other conventional phototherapies. 
 
 
Patients and Methods 
 
We evaluated 21 subjects (14 female, seven 
male), aged from 23 to 48 years, who suffered from 
stable or active vitiligo vulgaris for more than three 
years and less than six years. Lesions were variously 
localised (Table 2). 
Table 2: Distribution of vitiliginous macules in our patients 
Side of Lesion Number of Patients 
Face 17 
Trunk 9 
Arm 13 
 
In the past, all of them have been treated with 
different phototherapies, without good clinical results. 
In details, 18 patients had been treated with a 
complete session of PUVA therapy; the other 3 
stopped the treatment because of the gastric toxicity 
of psoralen. Successively, all patients completed the 
treatment with UVB broadband of clinical responses; 
patients had been successively treated with narrow-
band UVB (311nm) total body. None of them achieved 
a repigmentation rate more than 30%. In the recent 
past (5 months), none of them had been treated for 
the cutaneous disease. 
We decided to treat the patients with UVA - 1 
laser using Laser Alba 355®, a laser technology 
based on UVA - 1 spectrum with a wavelength of 355 
nm (Table 3). They had been irradiated once a week 
at a dosage of 120 J/cm², for 24 weeks. 
Table 3: Laser Alba 355 ® technical features [7] 
Laser Source Solid state pumped laser diode (DPSS) 
Active Material Neodymium-doped yttrium orthovanadate (Nd: YVO4) 
Wavelenght 355 nm 
Maximum Output 7W 
Beam Size 2.5 mm 
Beam Quality TEM00 
Beam Divergence 1.5 mrad 
Power Stability <1% 
Repetition  Pulse Rate 20-25 kHz 
Maximum Energy per Pulse 0.35 mJ 
Pulse Width 10-15 ns 
Brightness For 20000 hours 
Cooling System Air 
 
The time of emission and spot diameters were 
regulated by the operator, based on the clinical 
characteristics of the patients. 
For all patients, digital photographs of the 
vitiliginous lesions have been obtained before the start 
and at each treatment session. The response to the 
treatment was determined by assigning to each lesion 
a 0% score before therapy and a second percentage 
value at the end of the same, to represent the level of 
repigmentation (Table 4). 
Table 4: Classification of clinical response by the 
repigmentation rate 
Clinical response Repigmentation rate 
Excellent >75% 
Marked 50-75% 
Moderate 25-50% 
Minimal < 25% 
 
 
Results 
 
At the end of the treatment, we evaluated the 
repigmentation rate achieved by every single patient 
treated with Laser Alba 355®. 17 patients (81%) 
achieved excellent results, with a re - pigmentation 
rate bigger than 75%. Three patients (14%) achieved 
a marked improved of the clinical findings with a 
repigmentation rate between 50-75%. Only one 
patient showed minimal response to the 
phototherapeutic treatment. 
No differences in repigmentation had been 
described for the different localisation of the lesions. 
In general, the treatment had been well 
tolerated by all patients. Besides a mild, transient, 
post-therapy erythema and itching sensation, we did 
not observe other side effects. 
 
 
Discussion 
 
In this multicenter study, we evaluated the 
treatment of 21 patients affected by a stable or active 
form of localised vitiligo with Laser Alba 355®, an 
innovative targeted phototherapy device, with a peak 
of emission of 355 nm [7]. 
Like common UVA - 1 device, the biological 
effects of UVA - 1 laser are mainly mediated by the 
formation of reactive oxygen intermediates, during the 
mitochondrial oxidative phosphorylation, which may 
damage DNA, lipids, proteins and cellular organelles. 
This fact may exert different biochemical effects, such 
as inhibition of immune responses and stimulation of 
melanocytes [8][9]. 
The most important advantage in the use of 
Laser Alba 355®, is the possibility to treat only skin 
lesions, sparing uninvolved skin areas. This fact 
allows the operator to use higher doses achieving 
better results in less time and in a safer way, reducing 
the side effects due to radiation. 
 In conclusion, laser Alba 355® is an 
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innovative device of target UVA - 1 phototherapy. The 
present report suggests that UVA1 laser could be an 
applicable therapeutic option in patients with vitiligo, 
also for the ones who did not respond to the more 
conventional phototherapies. 
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